Cardiac potassium currents and channels Part II: Implications for clinical practice and therapy

International Journal of Cardiology

Volumn 62, Issue 1, 1997, Pages 1-12

  Monsuez, Jean Jacques ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; ALMOKALANT; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; APRIKALIM; ASTEMIZOLE; BIMAKALIM; CISAPRIDE; CROMAKALIM; DIAZOXIDE; DIURETIC AGENT; DOFETILIDE; ERYTHROMYCIN; FLECAINIDE ACETATE; IBUTILIDE FUMARATE; KETOCONAZOLE; MINOXIDIL; NICORANDIL; PINACIDIL; PLACEBO; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL STIMULATING AGENT; POTASSIUM ION; SEMATILIDE; SOTALOL; TEDISAMIL; TERFENADINE; UNINDEXED DRUG;

ARRHYTHMOGENESIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG CLASSIFICATION; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOKALEMIA; INTRAVENOUS DRUG ADMINISTRATION; LONG QT SYNDROME; ORAL DRUG ADMINISTRATION; POTASSIUM CURRENT; PRIORITY JOURNAL; REVIEW; SUPRAVENTRICULAR TACHYCARDIA; SURVIVAL; TORSADE DES POINTES;

EID: 0030728142     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(97)00169-1     Document Type: Article

References (79)

1. Vaughan Williams E.M. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol. 24:1984;129-147.
2. Colatsky T.J., Follmer C.H., Starmer C.F. Channel specificity in antiarrhythmic drug action: mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation. 92:1990;2235-2242.
3. Singh B.N. Arrhythmia control by prolongating repolarization: the concept and its potential therapeutic impact. Eur Heart J. 14(suppl H.):1993;14-23.
4. The Sicilian Gambit. Task Force of the Working Group on arrhythmias of the European Society of Cardiology. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991, 84: 1831-51.
5. Katristis D., Camm A.J. New class III antiarrhythmic drugs. Eur Heart J. 14(suppl H):1993;93-99.
6. + current (IKr) in AT-1 cells. Circulation. 91:1995;1799-1806.
7. Mori K., Hara Y., Saito T., Masuda Y., Nakaya H. Anticholinergic effects of class III antiarrhythmic drugs in guinea pig atrial cells. Circulation. 91:1995;2834-2843.
8. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989, 321: 406-412.
9. Mason J.W. Amiodarone. N Engl J Med. 316:1987;455-465.
10. Kowey P.R., Marinchak R.A., Rials S.J., Filart R. Intravenous amiodarone. J Am Coll Cardiol. 29:1997;1190-1198.
11. Levine J.M., Massumi A., Scheinman M.S.et al. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. J Am Coll Cardiol. 27:1996;67-75.
12. The CASCADE investigators randomized antiarrhythmic drug therapy in survivors of cardiac arrest (CASCADE study). Am J Cardiol 1993, 72: 280-287.
13. Burkart F., Pfisterer M., Kiowski W., Follath F., Burckhardt D. Effects of antiarrhythmic on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol. 16:1990;1711-1718.
14. Ceremuzynski F., Kleczar E., Kreminska-Pakula M.et al. Effects of amiodarone on mortality after myocardial infarction: a double bind, placebo-controlled, pilot study. J Am Coll Cardiol. 20:1992;1051-1062.
15. Cairns J.A., Connolly S.J., Roberts R., Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT. Lancet. 349:1997;675-682.
16. Julian D.G., Camm A.J., Frangin G., Janse M.J., Munoz A., Schwartz P.J., Simon P. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet. 349:1997;667-674.
17. Doval H.C., Nul D.R., Grancelli H.O., Perrone S.V., Bortman G.R., Curiel L. Randomized trial of low-dose amiodarone in patients with severe congestive heart failure. Lancet. 344:1994;493-498.
18. Singh S.N., Fletcher R.D., GrossFisher S.et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmias. N Engl J Med. 333:1995;77-82.
19. Nul D.R., Doval H.C., Grancelli H.O.et al. Heart rate is a marker of amiodarone mortality reduction in severe heart failure. J Am Coll Cardiol. 29:1997;1199-1205.
20. Pfammater J.P., Paul T., Lehmann C., Kallfelz H.C. Efficacy and proarrhythmia of oral sotalol in pediatric patients. J Am Coll Cardiol. 26:1995;1002-1007.
21. MacNeil D.J., Davies R.O., Deitchman D. Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol. 72:1993;44A-50A.
22. Barlow J.B., Obel I.W.P., Pocock W.A., McKibbin J.K. Sotalol: a unique class III antiarrhythmic agent. Am J Cardiol. 73:1994;932-933.
23. Mason J.W. for the Electrophysiologic study versus electrocardiographic monitoring (ESVEM) investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med. 329:1993;445-451.
24. Kühlkamp V., Mermi J., Mewis C., Braun U., Seipel L. Long-term efficacy of D,L-sotalol in patients with sustained ventricular tachycardia refractory to class I. antiarrhythmic drugs. Eur Heart J. 16:1995;1625-1631.
25. Sedgwick M.L., Dalrymple I., Rae A.P., Cobbe S.M. Effects of the new class III dofetilide on the atrial and ventricular intracardiac monophasic action potential in patients with angina pectoris. Eur Heart J. 16:1995;1641-1646.
26. r blockade: implications for the antifibrillatory efficacy of potassium channel blocking agents. J Am Coll Cardiol. 25:1995;1609-1614.
27. Waldo A.l., Camm A.J., deRuyter H.et al. Survival with oral D-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design and methods (the SWORD trial). Am J Cardiol. 75:1995;1023-1027.
28. Crijns H.J., WanGelder I.C., Kingma J.H., Dunsenman P.H., Gosselink A.T.M., Lie K.I. A trial flutter can be terminated by a class III antiarrhythmic drug but not by class Ic drug. Eur Heart J. 15:1994;1403-1408.
29. Falk R.H., Pollak A., Singh S.N., Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol. 29:1997;385-390.
30. Bianconi L., Dinelli M., Pappalardo A., Richiardi E., Castro A., Alboni P., Santini M., Dalrymple H.W., Radula D. Comparison of intravenously-administered dofetilide-versus amiodarone in the acute termination of atrial fibrillation and flutter. Circulation. 92(Suppl I):1995;I-774.
31. Yuan S., Wohlfart B., Rasmussen H.S., Olsson S., Blomstrom-Lundqvist C. Effect of dofetilide on cardiac repolarization in patients with ventricular tachycardia. Eur Heart J. 15:1994;514-522.
32. Bashir Y., Thomsen P.E., Kinema J.H.et al. Electrophysiologic profile and efficacy of intravenous dofetilide, a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Am J Cardiol. 76:1995;1040-1044.
33. Moller M. Diamond antiarrhythmic trials. Lancet. 348:1996;1597-1598.
34. Sager P.T., Nedemanee K., Antimisiaris M.et al. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans. Circulation. 88:1993;1072-1082.
35. Stambler B.S., Gottlieb S.S., Singh B.N., Ramanathan K.B., Ogilby J.D., Ellenbogen K.E. Hemodynamic effects of intravenous sematilide in patients with congestive heart failure: a class III antiarrhythmic agent without cardiodepressant effects. J Am Coll Cardiol. 26:1995;1679-1684.
36. Ellenbogen K.A., Stambler B.S., Wood M.A.et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter. J Am Coll Cardiol. 28:1996;130-136.
37. Bargheer K., Bode F., Klein H.U., Trappe H.J., Franz M.R., Lichtlen P.R. Prolongation of monophasic action potential duration and the refractory period in the human heart by tedisamil, a new potassium- blocking agent. Eur Heart J. 15:1994;1409-1414.
38. Roden D.M. Risks and benefits of antiarrhythmic therapy. N Engl J Med. 331:1994;785-791.
39. Wiesfeld A.C.P., Crijns H.J.G., Bergstrand R.H., Almgren O., Hillege B.E., Lie K.I. Torsades de pointes with Almokalant a new class III antiarrhythmic drug. Am Heart J. 126:1993;1008-1011.
40. Napolitano C., Diehl L., Schwartz P.L., Priori S.G. Modulation of the electrophysiologic effects af ambasilide induced by β-adrenergic stimulation in isolated ventricular myocytes. J Am Coll Cardiol. 23:1994;444A.
41. Isomoto S., Shimizu A., Konoe A.et al. Electrophysiologic effects of E-4031, a new class III antiarrhythmic agent, in patients with supraventricular tachyarrhythmias. Am J Cardiol. 71:1993;1464-1467.
42. Singh B.N., Ellenbogen K.A., Zoble R.G.et al. Electrocardiographic effects of oral MK-499, a new class III antiarrhythmic agent in patients with coronary disease. J Am Coll Cardiol. 23:1994;92A.
43. Hohnloser S.H., Klingenheben T., Singh B.N. Amiodarone - associated proarrhytmic effect - A review with special reference to torsade de pointes tachycardia. Ann Intern Med. 121:1994;529-535.
44. Berul C.I., Morad M. Regulation of potassium channels by non-sedating antihistamines. Circulation. 91:1995;2220-2225.
45. Antzelevitch C., Sicouri S. Clinical relevance in the generation of U waves, triggered activity and torsades de pointes. J Am Coll Cardiol. 23:1994;259-277.
46. Hondeghem L.M., Snyders D.J. Class III antiarrhythmic agents have a lot of potential but a long way to go: reduced effectiveness and dangers of reverse-use dependence. Circulation. 81:1990;686-690.
47. Sager P.T. Frequency-dependent electrophysiologic effects of dofetilide in humans. Circulation. 92(Suppl I):1995;I-774.
48. Okada Y., Ogawa S., Sadanaga T., Mitamura H. Assessment of reserve-use dependent blocking actions of class III antiarrhythmic drugs by 24-hour holter electrocardiography. J Am Coll Cardiol. 27:1996;84-89.
49. Kr. Circulation. 93:1996;407-411.
50. + channel. Circ Res. 78:1996;499-503.
51. Tice F.D., Binkley P.F., Cody R.J., Moeschberger M.L., Mohrland J.S., Wolf D.L., Leier C.V. Hemodynamic effect of oral nicorandil in congestive heart failure. Am J Cardiol. 65:1990;1361-1367.
52. Galie N., Varani E., Maiello L., Boriani G., Boschi S., Binetti G., Magnani B. Usefulness of nicorandil in congestive heart failure. Am J Cardiol. 65:1990;343-348.
53. Tsutamoto T., Kinoshita M., Hisanaga T., Maeda Y., Maeda K., Wada A., Fukai D., Yoshida S. Comparison of hemodynamic effects and plasma cyclic guanosin monophosphate of nicorandil and nitroglycerin in patients with congestive heart failure. Am J Cardiol. 75:1995;1162-1165.
54. Thadani U., Strauss W., Glasser S.P., Frishman W., Burger A.J., Locker J., Mohrland J.S. Evaluation of antianginal and antiischemic efficacy of nicorandil: results of a multicenter study. J Am Coll Cardiol. 23:1994;267A.
55. Camm J.A., Maltz M.B. A controlled single-dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris. Am J Cardiol. 63:1989;61J-65J.
56. Hugues L.O., Rose E.L., Lahiri A., Raftery E.B. Comparison of nicorandil and atenolol in stable angina pectoris. Am J Cardiol. 66:1990;679-682.
57. Auchampach J.A., Maruyana M., Cavero I., Gross G.J. Pharmacological evidence for a role of ATP dependent potassium channels in myocardial stunning. Circulation. 86:1992;311-319.
58. ATP channels: an endogenous protective mechanism during repetitive ischemia. Am J Physiol. 264:1993;H495-H504.
59. Verdouw P.D., Gho B.C.G., Dunker D.J. Ischaemic preconditioning: is it clinically relevant? Eur Heart J. 16:1995;1169-1176.
60. + channel? Circ Res. 77:1995;1030-1035.
61. Hearse D.J. Activation of ATP-sensitive potassium channels: a novel pharmacological approach to myocardial protection? Cardiovasc Res. 30:1995;1-17.
62. ATP channel opener Bimakalim on coronary blood low, monophasic action potential duration and infarct size in dogs. Circulation. 89:1994;1769-1775.
63. + channel blocker. Circulation. 90:1994;700-705.
64. Kerensky R.A., Kutcher M.A., Braden G.A., Applegate R.J., Solis G.A., Little W.C. The effect of intracoronary adenosine on preconditioning during PTCA. Circulation. 88:1993;I-588.
65. Yellon D.M., Alkhulaifi A.M., Pugsley W.B. Preconditioning the human myocardium. Lancet. 342:1993;276-277.
66. Wilde A.M., Janse M.J. Electrophysiological effects of ATP sensitive potassium channel modulation: implications for arrhythmogenesis. Cardiovasc Res. 28:1994;16-24.
67. Siegel P. Blockers of ATP sensitive potassium current are of potential benefit in ischaemic heart disease. Cardiovasc Res. 28:1994;31-32.
68. Cavero I., Premmereur J. ATP sensitive potassium channel openers are of potential benefit in ischaemic heart disease. Cardiovasc Res. 28:1994;32-33.
69. + channel response to acetylcholine and to G protein-mediated activation in atrial myocytes isolated from failing human hearts. Circulation. 90:1994;2213-2224.
70. f, in ventricular myocytes from human failing hearts. Circulation. 95:1997;568-571.
71. Tomaselli G.F., Beuckelmann D.J., Calgins H.G., Berger R.D., Kessler P.D., Lawrence J.H., Kass D., Feldman A.M., Marban E. Sudden cardiac death in heart failure; The role of abnormal repolarization. Circulation. 90:1994;2534-2539.
72. Benson D.W., MacRae C.A., Vesely M.R.et al. Missense mutation in the pore region of HERG causes familial long QT syndrome. Circulation. 93:1996;1791-1795.
73. Roden D.M., Lazzara R., Rosen M., Schwartz P.J., Towbin J., Vincent M. Multiple mechanisms in the long QT syndrome. Circulation. 94:1996;1996-2012.
74. Kiehn J., Lacerda A.E., Wible B., Brown A.M. Molecular physiology and pharmacology of HERG. Circulation. 94:1996;2572-2579.
75. Woosley R.L., Chen Y., Freiman J.P., Gillis R.A. Mechanisms of the cardiotoxic actions of terfenadine. J Am Med Assoc. 269:1993;1352-1356.
76. Roy M.L., Dumaine R., Brown A.M. HERG, a primary human ventricular target of the non-sedating antihistamine terfenadine. Circulation. 94:1996;817-823.
77. Wolfe S.M., Ahmad S.R. Cisapride and torsades de pointes. Lancet. 345:1995;508.
78. Daleau P., Turgeon J. Prolongation of QT interval induced by erythromycin may be explained by an inhibition of the rapid component of the delayed rectifier potassium IKr. Circulation. 90:1994;1-248.
79. Antzelevitch C., Sun Z.Q., Zhang Z.Q., Yan G.X. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol. 28:1996;1836-1848.